Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01673217
Completed
This phase I trial is studying the side effects and best dose of decitabine when given together with pegylated liposomal doxorubicin hydrochloride and vaccine therapy in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer. Drugs used in chemotherapy, such as decitabine and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccin... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Register for Updates
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
NCT01808456
Completed
Influenza infection in recipients of solid organ transplants recipients while on maintenance immunosuppressant therapy is associated with increased morbidity and mortality. Although influenza vaccination is recommended in these high-risk patients, safety and immunogenicity of commercially available different strengths of influenza vaccine have not been established. The primary study objective is to determine the safety and immunogenicity of Fluzone and Fluzone High-Dose, with a secondary object... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/20/2022
Locations: Inova Fairfax Hospital, Falls Church, Virginia
Conditions: Influenza, Human, Transplantation Infection
Register for Updates
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
NCT01808820
Completed
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
Gender:
ALL
Ages:
Between 13 years and 99 years
Trial Updated:
07/19/2022
Locations: University of Miami, Miami, Florida
Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Register for Updates
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
NCT03636906
Completed
The purpose of this study is to provide critical information on the safety, reactogenicity and immunogenicity profile of the investigational recombinant chimpanzee adenovirus Type 155-vectored RSV (ChAd155-RSV) vaccine in infants likely to be unexposed to RSV and will assess a single lower dose and a higher two dose regimen, before moving to future studies. This study will also assess if there is a risk of 'vaccine-induced enhanced RSV disease' after vaccination of these infants with the ChAd155... Read More
Gender:
ALL
Ages:
Between 6 months and 7 months
Trial Updated:
07/05/2022
Locations: GSK Investigational Site, Atlanta, Georgia +36 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Senescent Immunity in Elders and Vaccine Responses (SILVER)
NCT04077424
Completed
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Gender:
ALL
Ages:
Between 65 years and 125 years
Trial Updated:
06/16/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Flu Vaccine
Register for Updates
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
Completed
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/15/2022
Locations: Alliance for Multispecialty Research, LLC, Mobile, Alabama +62 locations
Conditions: Pneumococcal Disease
Register for Updates
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
NCT03934541
Completed
The purpose of this study is to evaluate the safety and immunogenicity of an HIV-1 gp41 MPER-656 liposome vaccine in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/15/2022
Locations: Alabama CRS, Birmingham, Alabama +5 locations
Conditions: HIV Infections
Register for Updates
Ontogeny of Measles Immunity in Infants
NCT00240916
Completed
This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
06/06/2022
Locations: Palo Alto Medical Foundation/Department of Pediatrics, Palo Alto, California +1 locations
Conditions: Measles
Register for Updates
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
NCT04460781
Completed
Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the estimated date of conception with regards to pregnancy, birth, and neonatal/infant outcomes Secondary Objective:
Gender:
ALL
Ages:
64 years and below
Trial Updated:
05/23/2022
Locations: Kaiser Permanente Northern California, Oakland, California
Conditions: Influenza
Register for Updates
Combination HTNV and PUUV DNA Vaccine
NCT03718130
Unknown
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/16/2022
Locations: University of Maryland, College Park, College Park, Maryland
Conditions: Hantaan Virus Disease, Puumala Virus
Register for Updates
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
NCT04544267
Suspended
The primary objective of the study is to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type. The secondary objectives of the study are: * To compare QIV-HD to QIV-SD: * in participants 6 months through 35 months of age for the prevention of laboratory-confirmed... Read More
Gender:
ALL
Ages:
Between 6 months and 35 months
Trial Updated:
05/03/2022
Locations: Investigational Site Number :8400008, San Diego, California +9 locations
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
NCT02915016
Completed
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy, HIV-uninfected adults.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/27/2022
Locations: Alabama CRS, Birmingham, Alabama +16 locations
Conditions: HIV Infections
Register for Updates